ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a single-center pilot study of 20 patients with AML/MDS. Eligible patients will be
enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem
cell transplant. Patients will receive weekly oral ONC 201 for a total of 52 weeks.